MGI Pharma Summarizes Data Presented at the 2007 American Society
of Clinical Oncology (ASCO) Annual Meeting
2007 American Society of Clinical Oncology (ASCO) AnnualMeeting --Dacogen(R) Activity in Older Patients with AML and inRefractory --Differentiation of the molecular interaction of Aloxi(R)with --Results of a Survival Analysis of Glioblastoma PatientsT...
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American
Society of Clinical Oncology (ASCO) Annual Meeting
CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 -
MGI Pharma, Inc.(Nasdaq:MOGN), a biopharmaceutical company focused in oncology andacute care, today provided highlights of data presentations madeduring the 2007 American Society of Clinical Oncology (ASCO) AnnualMeeting. Dacogen (decitabine) for Injection was the subject of fiveposters including the presentation of efficacy data in olderpatients with...
MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study
of Aquavan Injection in Patients Undergoing Bronchoscopy
MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 -
MGI PHARMA, INC.(NASDAQ: MOGN), a biopharmaceutical company focused in oncology andacute care, today announced that a randomized, double-blind,multi-center, pivotal phase 3 trial of Aquavan(R) (fospropofoldisodium) Injection for sedation of patients undergoingbronchoscopy successfully met its primary endpoint of sedationsuccess as well as all sec...